Cryo-Cell International stock analysis
Cryo-Cell International (ZCY) Stock Price & Analysis
ZCY Stock Chart & Stats
- Day’s Range
- EUR 3.50 - EUR 3.52
- 52-Week Range
- EUR 2.32 - EUR 4.52
- Previous Close
- EUR 4.10
- Volume
- N/A
- Average Volume (3M)
- 100
- Market Cap
- EUR 30.49M
- Enterprise Value
- EUR 38.46M
- Total Cash (Recent Filing)
- EUR 4.23M
- Total Debt (Recent Filing)
- EUR 577.20K
- Price to Earnings (P/E)
- ―
- Beta
- 0.25
- Next Earnings
- Feb 26, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Positive Cash Generation
Positive operating and free cash flow provide internal funding for ongoing operations and reduce immediate reliance on external capital. Cash generation has remained positive from 2024 through TTM, supporting business resilience even while reported net income is negative.
Strong Gross Margin
A gross margin near 77% indicates the core service offering retains substantial value after direct costs. If maintained, this creates room to absorb operating expenses, invest in customer acquisition and preserve cash generation as the business scales.
Recurring Storage Revenue Model
The combination of upfront processing revenue and recurring long-term storage fees can build a durable revenue base as new enrollments accumulate. Client retention and prepaid plans may improve revenue visibility and support continued cash generation over multiple periods.
Bears Say
Negative Stockholders’ Equity
Deeply negative equity signals a strained capital structure and reduces financial flexibility, even though total debt is lower than in earlier years. The company may have less capacity to absorb operating setbacks or fund initiatives without rebuilding its balance sheet.
Persistent Net Losses
Current losses indicate that the company’s strong gross margin is not translating consistently into bottom-line earnings. Near-breakeven operating profit leaves limited room for cost increases or execution setbacks, while earnings volatility makes future profitability less dependable.
Weak Revenue And Cash-Flow Momentum
Flat-to-declining revenue limits the company’s ability to expand its customer base and spread fixed costs, while sharply lower free cash flow indicates deteriorating cash momentum. Together, these trends could constrain investment and make the recent cash generation less durable.
ZCY FAQ
What was Cryo-Cell International’s price range in the past 12 months?
What is Cryo-Cell International’s market cap?
When is Cryo-Cell International’s upcoming earnings report date?
How were Cryo-Cell International’s earnings last quarter?
Is Cryo-Cell International overvalued?
Does Cryo-Cell International pay dividends?
What is Cryo-Cell International’s EPS estimate?
How many shares outstanding does Cryo-Cell International have?
What happened to Cryo-Cell International’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cryo-Cell International?
What is the TipRanks Smart Score and how is it calculated?
Cryo-Cell International Stock Smart Score
Company Description
Cryo-Cell International
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- David Portnoy
- Employees
- 74
- Website
- www.cryo-cell.com
- Address
- 700 Brooker Creek Boulevard, Oldsmar, FL, 34677, US
Cryo-Cell International (ZCY) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 2 | 10 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 4 | 0 | 8 |












